دورية أكاديمية
أعرض في EDS

Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.

التفاصيل البيبلوغرافية
العنوان: Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
المؤلفون: Akhter A; Division of Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, University of Calgary/Calgary Laboratory Services (CLS), Calgary, AB, Canada., Masir N, Elyamany G, Phang KC, Mahe E, Al-Zahrani AM, Shabani-Rad MT, Stewart DA, Mansoor A
المصدر: Journal of neuro-oncology [J Neurooncol] 2015 Jan; Vol. 121 (2), pp. 289-96. Date of Electronic Publication: 2014 Nov 13.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2005- : New York : Springer
Original Publication: Boston : M. Nijhoff, 1983-
مواضيع طبية MeSH: Central Nervous System Neoplasms/*metabolism , Lymphoma, Large B-Cell, Diffuse/*metabolism , Receptors, Antigen, B-Cell/*metabolism , Toll-Like Receptors/*metabolism, Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans
مستخلص: Primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) is a distinct and aggressive lymphoma that is confined to CNS. Since, central nervous system is barrier-protected and immunologically silent; role of TLR/BCR signaling in pathogenesis and biology of CNS DLBCL is intriguing. Genomic mutations in key regulators of TLR/BCR signaling pathway (MYD88/CD79B/CARD11) have recently been reported in this disease. These observations raised possible implications in novel targeted therapies; however, expression pattern of molecules related to TLR/BCR pathways in this lymphoma remains unknown. We have analyzed the expression of 19 genes encoding TLR/BCR pathways and targets in CNS DLBCLs (n = 20) by Nanostring nCounter™ analysis and compared it with expression patterns in purified reactive B-lymphocytes and systemic diffuse large B cell lymphoma (DLBCL) (n = 20). Relative expression of TLR4, TLR5, TLR9, CD79B and BLNK was higher in CNS DLBCLs than in control B-lymphocytes; where as TLR7, MALT1, BCL10, CD79A and LYN was lower in CNS DLBCLs (P < 0.0001). When compared with systemic DLBCL samples, higher expression of TLR9, CD79B, CARD11, LYN and BLNK was noted in CNS DLBCL (>1.5 fold change; P < 0.01). The B cell receptor molecules like BLNK and CD79B were also associated with higher expression of MYD88 dependent TLRs (TLR4/5/9). In conclusion, we have shown over expression of TLR/BCR related genes or their targets, where genomic mutations have commonly been identified in CNS DLBCL. We have also demonstrated that TLR over expression closely relate with up regulation of genes associated with BCR pathway like CD79B/BLNK and CARD11, which play an important role in NF-kB pathway activation. Our results provide an important insight into the possibility of TLR and/or B-cell receptor signaling molecules as possible therapeutic targets in CNS DLBCL.
References: Leukemia. 2014 Mar;28(3):719-20. (PMID: 24253023)
Exp Hematol. 2000 May;28(5):558-68. (PMID: 10812246)
Nature. 2011 Feb 3;470(7332):115-9. (PMID: 21179087)
J Pathol. 2005 Feb;205(3):293-301. (PMID: 15682443)
APMIS. 2012 Nov;120(11):872-81. (PMID: 23009111)
Front Immunol. 2014 Jul 31;5:367. (PMID: 25132836)
Cancer. 2013 Feb 15;119(4):782-91. (PMID: 22915070)
J Hematol Oncol. 2014 Aug 12;7:57. (PMID: 25112836)
Curr Protoc Mol Biol. 2011 Apr;Chapter 25:Unit25B.10. (PMID: 21472696)
Acta Neuropathol. 2014 Feb;127(2):175-88. (PMID: 24240734)
Cytokine. 2010 Jan;49(1):1-9. (PMID: 19775907)
Leukemia. 2011 Dec;25(12):1797-807. (PMID: 21818113)
Clin Cancer Res. 2012 Oct 1;18(19):5203-11. (PMID: 22837180)
Clin Cancer Res. 2005 Feb 15;11(4):1490-9. (PMID: 15746051)
J Natl Cancer Inst. 2006 May 3;98(9):574-5. (PMID: 16670380)
J Neurooncol. 2011 Feb;101(3):487-93. (PMID: 20556477)
Acta Neuropathol. 2010 Nov;120(5):667-81. (PMID: 20640902)
Curr Top Microbiol Immunol. 2002;270:47-61. (PMID: 12467243)
Acta Neuropathol. 2011 Dec;122(6):791-2. (PMID: 22020631)
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jan;28(1):37-40. (PMID: 18227022)
Cell. 2006 Feb 24;124(4):783-801. (PMID: 16497588)
Nature. 2010 Jan 7;463(7277):88-92. (PMID: 20054396)
Blood. 2006 May 1;107(9):3716-23. (PMID: 16418334)
J Pathol. 2008 Oct;216(2):209-17. (PMID: 18729069)
Genes Chromosomes Cancer. 2002 Sep;35(1):38-48. (PMID: 12203788)
Nat Rev Immunol. 2004 Jul;4(7):499-511. (PMID: 15229469)
J Neuropathol Exp Neurol. 2007 Mar;66(3):230-7. (PMID: 17356384)
Br J Cancer. 2011 Oct 25;105(9):1414-8. (PMID: 21915121)
Curr Mol Med. 2009 Apr;9(3):324-35. (PMID: 19355914)
Blood. 2011 May 12;117(19):5019-32. (PMID: 21300984)
Blood. 2008 Mar 15;111(6):3200-10. (PMID: 18184868)
Blood. 2008 Sep 15;112(6):2205-13. (PMID: 18591383)
J Exp Clin Cancer Res. 2013 Apr 05;32:18. (PMID: 23561041)
Acta Neuropathol. 2012 Dec;124(6):905-6. (PMID: 23138649)
Leukemia. 2009 Oct;23(10):1875-84. (PMID: 19494841)
Lancet Oncol. 2010 Nov;11(11):1036-47. (PMID: 20970380)
المشرفين على المادة: 0 (Receptors, Antigen, B-Cell)
0 (Toll-Like Receptors)
تواريخ الأحداث: Date Created: 20141114 Date Completed: 20151026 Latest Revision: 20181113
رمز التحديث: 20231215
DOI: 10.1007/s11060-014-1655-3
PMID: 25391967
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-7373
DOI:10.1007/s11060-014-1655-3